Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : RNA-based Therapy
Therapeutic Area : Genetic Disease
Study Phase : Discovery Platform
Sponsor : Eli Lilly
Deal Size : Undisclosed
Deal Type : Collaboration
Genetic Leap, Lilly Collaborate to Advance Genetic Medicine Development with AI
Details : The collaboration will leverage Genetic Leap's RNA-targeted AI platform to generate oligonucleotide drugs against targets selected by Lilly in high priority therapeutic areas.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : $409.0 million
September 05, 2024
Lead Product(s) : RNA-based Therapy
Therapeutic Area : Genetic Disease
Highest Development Status : Discovery Platform
Sponsor : Eli Lilly
Deal Size : Undisclosed
Deal Type : Collaboration
LOOKING FOR A SUPPLIER?